Vioxx news from FierceHealthcare
News
Merck agrees to $58M settlement on Vioxx ads
Merck has agreed to a $58 million settlement with 29 states and the District of Columbia to settle allegations that it downplayed heart risks created by Vioxx in direct-to-consumer advertising. Under Read more...
Studies show problems with four big-name drugs
It looks like yet another set of popular drugs are facing allegations that they pose safety risks. Drugs named this week in unfavorable studies include Fosamax, which may create heart problems for Read more...
ALSO NOTED: Demand for health IT pros to soar; Pharmas lobbying hard in DC; and much more...
> Industry researchers are predicting that it will take a huge increase in the volume of professionals available (more than 40,000) to meet the near-term demand for skilled health IT pros. Read more...
Reports suggest that Merck downplayed Vioxx risks
Another day, another report suggesting that a pharmaceutical company tried to bury data impugning the safety of one of its products. This time, a study has been published in The Journal of the Read more...
WellPoint, FDA collaborate on tracking drug safety
Now here's an interesting partnership--one that likely will generate some valuable results. WellPoint and the FDA have agreed to work together to create a real-time drug-surveillance system to look Read more...
ALSO NOTED: AIDS vaccine back at square one; What's behind the FDA's low drug approval rating?; and much more...
> After trying and failing repeatedly to develop an AIDS vaccine, federal officials say they're going back to the drawing board to come up with some new ideas. Read more...
ALSO NOTED: TN Medicaid to test e-prescribing program; NIH alerts patients of stolen personal information; and much more...
> Tennessee's Medicaid program and one of its Medicaid managed care providers have announced that they plan to kick off an e-prescribing pilot program in 13 of the state's rural counties. Read more...
Merck agrees to pay$650M+ to settle suits
Merck has agreed to pay more than $650 million to settle two whistleblower suits, the U.S. Justice Department has announced. One of the suits claimed that the pharma paid providers to use its Read more...
Despite safety issues, Vioxx still in demand
For every regulatory action, it seems that there must be a backlash. This time, it's a move by consumers to bring back the controversial drug, Vioxx. Patients who once depended on the drug for Read more...
Get more Vioxx coverage at:
Paid Research Reports
- Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard
- Impact of Pharmacogenomics on Public Healthcare Policy
- The Cardiovascular Disorders Market Outlook to 2012
- 2008 Trends to Watch: Pharmaceutical Technology
- Pharmaceutical Pricing and Reimbursement: Strategies for market access across the US, Europe, Japan and other key geographies